IDH1 and central nervous system cancer: A meta-analysis by Xia et al., including 55 studies and 9,487 patients, demonstrated a significant survival advantage in gliomas with IDH1/2 mutations: OS (HR = 0.39; 95% CI: 0.34-0.45; p < 0.001) and progression-free survival (PFS) (HR = 0.42; 95% CI: 0.35-0.51; p < 0.001) [9].